Clinical Trials

95 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05880394 2024-02-12

Study of Dotatate Imaging in Breast Cancer

Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

49 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05629429 2024-01-17

Olaparib Maintenance Therapy in Metastatic Breast Cancer

300 enrolled

Breast Neoplasms

NCT03812393 2023-12-18

FACT-2

27 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04197687 2023-12-18

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

480 enrolled

Breast Neoplasms

NCT06152822 2023-12-01

Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06151249 2023-11-30

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

32 enrolled

Breast Neoplasms, Fatigue

NCT03906669 2023-11-22

WinPro

200 enrolled

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04267315 2023-10-16

Trigger Point Injections for Post-Mastectomy Pain Syndrome

72 enrolled

Breast Neoplasms, Myofascial Pain Syndromes

NCT04591431 2023-10-03

ROME

BreastGastrointestinalThoracic

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04883814 2023-09-28

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

124 enrolled

Breast Neoplasms

NCT05800834 2023-09-28

MorphineGEL

106 enrolled

BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

NCT05296577 2023-09-25

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

134 enrolled

Breast Neoplasms

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

120 enrolled

Breast Neoplasms

NCT03712956 2023-09-21

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

63 enrolled

Breast Neoplasms

NCT04165993 2023-09-21

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

68 enrolled

Breast Neoplasms

NCT05353361 2023-09-15

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

402 enrolled

Breast Neoplasms

NCT05823623 2023-09-14

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Breast Neoplasms

NCT06000033 2023-08-21

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

35 enrolled

Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT05967884 2023-08-01

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

20 enrolled

Breast Neoplasms

NCT05966441 2023-07-28

Role of Curcumin in Paclitaxel Induced PN

80 enrolled

Breast Neoplasms

NCT02679040 2023-07-03

HIST-RIC

101 enrolled

Breast Neoplasms

NCT05889728 2023-06-05

Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer

20 enrolled

Breast Neoplasms

NCT05885776 2023-06-02

PYTHON

48 enrolled

Breast Neoplasms

NCT05880927 2023-05-30

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

150 enrolled

Breast Neoplasms

NCT05878678 2023-05-26

Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position

200 enrolled

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

41 enrolled

Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT04733417 2023-04-13

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

35 enrolled

Breast Neoplasms

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Neoplasms

NCT05800756 2023-04-06

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Breast Neoplasms

NCT00431704 2023-03-24

VinCaT

39 enrolled

Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients